RHON-KLINIKUM AG reported its results for the third quarter of 2026, showing an 8.3% increase in patients treated and a rise in consolidated profit to EUR 32.7 million, up from EUR 25.1 million in the prior-year period. The group treated 764,248 patients on an inpatient and outpatient basis from January to September 2026, compared with 705,830 in the same period of 2025. Consolidated revenue reached EUR 1,303.8 million, exceeding the previous year's EUR 1,262.1 million, while EBITDA rose to EUR 83.9 million from EUR 71.8 million.
The earnings growth was supported by a 3.25% surcharge on hospital services, accounted for under "other income" through October 2026, intended to offset increases in personnel and non-personnel costs. The increase in consolidated profit was primarily driven by higher capacity utilization at clinics and medical care centers, along with patient growth, particularly in the outpatient sector. The company's strong capital base, with an equity ratio of 74.7%, provides a solid foundation for optimizing inpatient and outpatient care structures, according to the release published on NEWMEDIAWIRE.
Dr. Gunther K. WeiB, member of the Board of Management of RHON-KLINIKUM AG, stated: "Our successful third quarter shows that financial stability and medical excellence are inseparable, going hand in hand. Underlying this success is the tremendous trust our patients put in us. This sustainable basis is what allows us to continue making targeted investments in state-of-the-art medical technology and care offerings."
The company highlighted two investments demonstrating its innovation course. At Universitatsklinikum Marburg, a state-of-the-art photon-counting computer tomograph was put into service, making RHON-KLINIKUM AG the only hospital group in Germany with four newest-generation units in operation. In Frankfurt (Oder), a new hybrid operating theatre has expanded the treatment range, strengthening interdisciplinary structures and enhancing care offerings in the Ostbrandenburg region.
Dr. Stefan Stranz, also a member of the Board of Management, commented: "This forward-looking investment strategy ensures that we can continue to operate effectively in a market environment facing far-reaching and sweeping change. Thanks to our solid financial basis and our collaboration within the ASKLEPIOS Group network, we can take on and actively shape this transformation process from a position of strength."
For the full 2026 financial year, RHON-KLINIKUM AG expects revenues of EUR 1.7 billion within a range of plus or minus 5%, and EBITDA between EUR 110 million and EUR 125 million. The company also anticipates a moderate improvement in the number of cases and cost weights. However, the financial year will be significantly impacted by the unfolding legislative process, particularly the Hospital Reform Adjustment Act (KHAG) that entered into force on 15 April 2026 and the Statutory Health Insurance Contribution Rate Stabilisation Act (GKV-BStabG) adopted on 10 July 2026. While these laws aim to enhance quality and efficiency, they will put hospitals under greater financial pressure in the short term, making the forecast subject to particular uncertainties.
The quarterly statement for Q3 2026 is available on the Internet. RHON-KLINIKUM AG, a company of the ASKLEPIOS Group, operates five highly specialized maximum- and intermediate-care facilities and employs over 19,100 people. More information is available at www.rhoen-klinikum-ag.com.
